Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
Retrieved on:
Tuesday, October 17, 2023
Nexus, Food, Expo Hall, T2D, Standard of care, QALY, Risk, Hospital, Orlando World Center Marriott, Death, Mortality, AMCP, Academy of Managed Care Pharmacy, HF, FDA, ED, Heart failure, Quality-adjusted life year, National meetings of the Workers' Party of Korea, Cypress, Life imprisonment, Pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, SOC, Patient, Health insurance, Pharmaceutical industry
THE WOODLANDS, Texas, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today highlighted upcoming presentations of two studies demonstrating positive financial impact of INPEFA® (sotagliflozin) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting, October 16-19, 2023, at the Orlando World Center Marriott, Expo Hall, Cypress 1 and 2, Orlando, Florida.
Key Points:
- The budget impact was modeled as the change in medical and pharmacy costs from using sotagliflozin in addition to the standard of care (SoC) compared with the SoC alone among U.S. patients hospitalized with heart failure (HF).
- Costs included pharmacy, inpatient, emergency department visits, and other medical and adverse event costs.
- Amongst treated patients on sotagliflozin, commercial payers incurred increased pharmacy costs of $7,276 per patient per year as compared to patients on SoC alone.
- Clinical outcomes of interest were hospital readmissions, emergency department (ED) visits, and all-cause deaths after an HF hospitalization.